Evidence map›Paper›PMID 33387925›Full record

ArticleThe Science of the total environment2021

A cost-effective plan for global testing - an infection rate stratified, algorithm guided, multiple-level, continuously pooled testing strategy.

Tianshu Gu, Lan Yao, Xia Meng, J Carolyn Graff, Donald Thomason, Jing Li, Wei Dong, Yan Jiao, Lotfi Aleya, Marcello Maida and 10 more

Abstract read
In one paragraph

Article in The Science of the total environment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Democracy and case fatality rate of COVID-19 at early stage of pandemic: a multicountry study.Environmental science and pollution research international · 2022
    Article
  5. Pooled Testing Strategies for SARS-CoV-2 diagnosis: A comprehensive review.Diagnostic microbiology and infectious disease · 2021
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tianshu GuCollege of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN 38103, USA; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, PR China.
Lan YaoHealth Outcomes and Policy Research, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN 38103, USA; Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Key Laboratory of Etiologic Epidemiology, Education Bureau of Heilongjiang Province & Ministry of Health [23618104], 157 Baojian Road, Harbin, Heilongjiang 150081, PR China.
Xia MengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, PR China.
J Carolyn GraffCollege of Nursing, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Donald ThomasonDepartment of Physiology and Biophysics, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Jing LiDepartment of Orthopedic Surgery and Biomedical Engineering-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Wei DongDepartment of Orthopedic Surgery and Biomedical Engineering-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Yan JiaoDepartment of Orthopedic Surgery and Biomedical Engineering-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Lotfi AleyaChrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, F-25030 Besançon Cedex, France.
Marcello MaidaGastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, 93100 Caltanissetta, Italy.
Cong-Yi WangThe Center for Biomedical Research, Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China.
Barbara ZangerlCentre for Eye Health and School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia.
Sem GeniniUnione Contadini Ticinesi, via Gorelle 7, 6592 S. Antonino, Switzerland.
Kunal RayAcademy of Scientific & Innovative Research [AcSIR], CSIR - HRDC Campus, Ghaziabad, Uttar Pradesh 201002, India.
Emanuel GoldmanDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA.
Jiafu JiBeijing Cancer Hospital and Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, PR China.
Andrei V AlexandrovDepartment of Neurology, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Dianjun SunCenter for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Key Laboratory of Etiologic Epidemiology, Education Bureau of Heilongjiang Province & Ministry of Health [23618104], 157 Baojian Road, Harbin, Heilongjiang 150081, PR China.
Weikuan GuDepartment of Orthopedic Surgery and Biomedical Engineering-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Research Service, Memphis VA Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA. Electronic address: wgu@uthsc.edu.
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, PR China. Electronic address: yongjunwang@ncrcnd.org.cn.

Funding

Study of the Genetic Basis for Fibrotic Diseases in a Mouse ModelI01BX000671 · VA · MEMPHIS VA MEDICAL CENTER · PI GU, WEIKUAN · 2012 to 2015
–
BLRD VA I01 BX000671
6 · The paper itself

Abstract

The most effective measure to prevent or stop the spread of infectious diseases is the early identification and isolation of infected individuals through comprehensive screening. At present, in the COVID-19 pandemic, such screening is often limited to isolated regions as determined by local governments. Screening of potentially infectious individuals should be conducted through coordinated national or global unified actions. Our current research focuses on using resources to conduct comprehensive national and regional regular testing with a risk rate based, algorithmic guided, multiple-level, pooled testing strategy. Here, combining methodologies with mathematical logistic models, we present an analytic procedure of an overall plan for coordinating state, national, or global testing. The proposed plan includes three parts 1) organization, resource allocation, and distribution; 2) screening based on different risk levels and business types; and 3) algorithm guided, multiple level, continuously screening the entire population in a region. This strategy will overcome the false positive and negative results in the polymerase chain reaction (PCR) test and missing samples during initial tests. Based on our proposed protocol, the population screening of 300,000,000 in the US can be done weekly with between 15,000,000 and 6,000,000 test kits. The strategy can be used for population screening for current COVID-19 and any future severe infectious disease when drugs or vaccines are not available.

Indexed as

COVID-19Pharmaceutical PreparationsAlgorithmsCost-Benefit AnalysisHumansPandemicsSARS-CoV-2Pharmaceutical PreparationsCoronavirusCOVID-19InfectionPopulationScreeningTest

Identifiers

PMID33387925
PMCPMC7833620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.